Novel Drug Targeting for IVF

  • Novel Route of Uterine Preparation for Improved Gene Expression that mimics Normal, Healthy Pregnancy


    Refined Uterine Preparation Prior to Embryo Transfer for the Sole Purpose of Enhancing Embryonic Implantation

    About Us


    We are an accomplished team of scientists, physicians and business professionals who are focused upon improving pregnancy outcome in reproductive medicine.

    Our sole purpose is to resolve the problem of failed embryonic implantation (the main hurdle in achieving pregnancy in IVF) to ultimately encourage Single Embryo Transfer (SET) which is more likely to result in a healthy singleton pregnancy for the infertile couple.

    Novel Route of Hormonal Administration

           (to the Inside of the Uterus)


    Improved Molecular Bioavailability


    Sustained Genomic Expression


    Extended Window of Implantation


    Increased Likelihood of Pregnancy



    Scientific validation

    Healthy women can only become pregnant approximately 4 days each month (96 hrs.) during which time their uterine lining is naturally prepared for implantation of a fertilized egg. This very special time period is termed; "the Window of Implantation" (WOI).


    In IVF it is necessary to artificially re-create this special phenomenon by administering the hormone progesterone which produces a receptive uterus.


    For over 40 years, since the success of the first test tube baby, doctors have been administering progesterone to the outside of the uterus via IM injection and vaginal suppositories. Unfortunately, these conventional methods moreoften fail to provide the proper range of progesterone sufficiently long enough for the complex gene expression within the lining of the uterus which establishes the WOI.


    There is now human genomic evidence that demonstrates how we've been artificially creating a receptive uterus for only 32 hrs. (maximum) in all IVF cycles for over four decades.


    Genomic validation is supported by CooperGenomics' ER Map Technology, "Endometrial Receptivity Map" whereby expression of required endometrial genes is dramatically limited, producing a significantly abbreviated Window of Implantation.


    This means that during any given IVF treatment, pregnancy can only occur during a very narrow 32 hr. time period, (at best).


    Incintas Therapeutics resolved this problem by administering progesterone to the inside of the uterus using an extended-release formulation of progesterone to provide optimal bioavailability of hormone for up to 96 hrs. The sustained proper range of bioavailability of hormone results in prolonged endometrial gene expression and a lengthened WOI, increasing the likelihood for implantation of the embryo in the process.


    Incintas' liquid hormonal therapeutic is administered by the clinician 3 days prior to anticipated embryo transfer via standard IVF protocol using an ultrasound guided ET catheter, to ideally prime the endometrial lining for implantation and establishment of pregnancy.


    Incintas' novel intrauterine route of progesterone administration sustains endometrial biomarker expression up to three times longer than all conventional uterine preparation methods by having the hormone administered where it needs to be....inside the uterus, not the bloodstream.


    Plus , we patented the targeted drug delivery methods and formulation capabilities in the US and Europe, (worldwide rights pending).






    It is no surprise that after four decades since the first IVF baby was born, we've only reached a 30% plateau of fertility success (on average) when a single embryo is transferred to the uterus during an IVF cycle.



    Current Duration WOI/Healthy WOI:

    32/96 hours = ~30%


    Most importantly, until this poor manner of uterine preparation is resolved, there is limited possibility of achieving dramatic improvements in IVF outcome.


    Incintas has the answer.




    The Incintas Advantage

    What is most striking about recent genomic data is that when the genes required for successful implantation of the embryo were expressed optimally, during that 32 hr. window, pregnancy was achieved over 80% of the time.


    Please see the latest genomic clinical evidence: https://doi.org/10.1016/j.fertnstert.2016.07.622


    The Incintas Advantage is unlike all other uterine preparation methods in assisted reproduction in that it can achieve sustained gene expression significantly longer, to mimic the physiology of a woman's natural ovulatory cycle in normal healthy pregnancy.






    Partnering Advantages

    -Early to Mid Stage Entry

    -Sound Clinical (Human) Data

    -Large Existing Market Potential (2M IVF Cycles/yr.) Rapid Scaling

    -Growing Market

    -Established Intellectual Property

    -Seasoned Business Partners

    -Supported by Experienced IVF Luminaries

    from around the World

    -Shortened Regulatory Agenda to Market

    505(b)(2) Candidate

    -Formulations Established with IP


    -Life Saving/Life Changing Technology
















  • Executive Partners

    On a mission to help millions of fertility challenged families

    Jesse Pizolato


    Founding Partner

    Michael Barton


    Founding Partner

    Harald F. Stock, PhD

    Strategic Advisor

    Business Development

    Kun Zoo Kim, MD

    Founding Partner

  • Scientific Partners

    The Experts Behind Incintas Therapeutics' Breakthrough Technology

    Carlo Bulletti, MD, CSO

    IVF Luminary

    Dr. Carlo Bulletti is Director of the Physiopathology Unit of Reproduction at Rimini General Hospital, University of Bologna, Italy. He has authored 10 medical text books, 130 medical book chapters and more than 160 scientific articles.


    Robert Taylor,

    MD, PhD, CMO

    Endometriosis Luminary

    Robert N. Taylor, MD PhD is
    Professor, Reproductive Endocrinology and Infertility
    University of Utah Health
    Obstetrics & Gynecology Research Network
    30 North 1900 East, Suite 2A242
    Salt Lake City, Utah USA 84132

    Sarah Berga, MD

    Medical Advisor



    Dr. Sarah Berga is

    Professor and Director, Division of Reproductive Endocrinology and Infertility, University of Utah and

    has written extensively on the science and physiopathology of infertility in men and women..

  • Graphical Analysis

    IM and PV endometrial concentrations (human biopsy data)

    ..........vs. the Incintas Advantage

    Progesterone Concentration vs. Time

    Genomic Data now confirms Endometrial Biopsy Data as depicted in a 1-1/3 day bioavailability of the proper hormonal concentration in order to achieve implantation of the embryo

  • In Memory Of



    Mitchell V. Pizolato,

    Nov. 23 -Nov. 29, 2000.

    Multiple IVF Birth















    Lance D. Pizolato

    Nov. 23 - Dec. 1, 2000

    Multiple IVF Birth

    Rest in Peace, my dear sons.